<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534118</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564827</org_study_id>
    <secondary_id>RPCI-I-00703</secondary_id>
    <nct_id>NCT00534118</nct_id>
  </id_info>
  <brief_title>Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant</brief_title>
  <official_title>Cellular Infusions in Patients With Recurrent or Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in&#xD;
      patients with hematologic cancer that has come back after a donor stem cell transplant.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating&#xD;
      patients with recurrent or persistent hematologic cancer after donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine if the complete response rate exceeds 10% in patients with recurrent or&#xD;
           persistent hematologic malignancies treated with donor lymphocyte infusion.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Estimate the complete response rate in these patients.&#xD;
&#xD;
        -  Assess the toxicity of donor lymphocyte infusion in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive up to four donor lymphocyte infusions at least 1 month apart in the&#xD;
      absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host&#xD;
      disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2003</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>100 days post DLI</time_frame>
    <description>continued or induced complete remission after DLI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Complete Response in Months (Maximum 12)</measure>
    <time_frame>1 year post DLI</time_frame>
    <description>For participants who achieve a complete remission after DLI, the duration of time until 1) relapse or 2) death in remission or 3) subsequent DLI or 4) last followup (at 1 year after DLI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-host Disease</measure>
    <time_frame>100 days post DLI</time_frame>
    <description>development of grade III-IV acute graft-versus-host disease (GVHD) per Glucksberg criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>donor lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Has undergone allogeneic stem cell transplantation (ASCT) for hematologic malignancy&#xD;
             at least 30 days ago&#xD;
&#xD;
               -  No failure to engraft following transplant&#xD;
&#xD;
               -  No active acute or chronic graft-versus-host disease (GVHD)&#xD;
&#xD;
                    -  Minimal GVHD allowed&#xD;
&#xD;
          -  Persistent or relapsed disease after ASCT, including 1 of the following:&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML), meeting any of the following criteria:&#xD;
&#xD;
                    -  Molecular relapse (may be treated with imatinib mesylate after transplant),&#xD;
                       as defined by any of the following:&#xD;
&#xD;
                         -  ASCT was non-T-cell depleted, a negative bcr/abl was documented by PCR&#xD;
                            post-transplant, and bcr/abl is now detectable by 2 consecutive PCR&#xD;
                            determinations &gt; 30 days apart&#xD;
&#xD;
                         -  ASCT was non-T-cell depleted and bcr/abl is detectable by PCR at any&#xD;
                            time after day 180 post-transplant&#xD;
&#xD;
                    -  Cytogenetic relapse after 3-6 months of imatinib mesylate&#xD;
&#xD;
                    -  Relapsed chronic phase, accelerated phase, or blastic phase CML after 3-6&#xD;
                       months of imatinib mesylate&#xD;
&#xD;
                         -  Must currently be in chronic phase or accelerated phase CML only&#xD;
&#xD;
                         -  Patients with blastic phase CML must attain a second chronic phase&#xD;
&#xD;
               -  Acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic&#xD;
                  syndromes, meeting any of the following criteria:&#xD;
&#xD;
                    -  Molecular relapse, as evidenced by &lt; 5% blasts in the bone marrow and the&#xD;
                       patient's leukemia-specific molecular abnormality detectable by PCR&#xD;
&#xD;
                    -  Cytogenetic relapse, as evidenced by &lt; 5% blasts in the bone marrow and the&#xD;
                       patient's leukemia-specific chromosome abnormality detectable by standard&#xD;
                       cytogenetics at any time after day 60 post-transplant&#xD;
&#xD;
                    -  Hematologic relapse, as evidenced by &gt; 20% blasts in bone marrow or soft&#xD;
                       tissue recurrence&#xD;
&#xD;
                         -  Must be treated with chemotherapy after transplant, but before study&#xD;
                            donor lymphocyte infusion (DLI)&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
                    -  Relapsed disease or recurrence of M-protein after thalidomide or other&#xD;
                       salvage treatment&#xD;
&#xD;
                         -  Prior post-transplant documentation of disappearance of M-protein by&#xD;
                            immunofixation&#xD;
&#xD;
                    -  Residual or progressive disease&#xD;
&#xD;
                    -  Rising M-protein level at any time post-transplant (measured at 3-month&#xD;
                       intervals)&#xD;
&#xD;
                    -  Original M-protein detectable at 6 months post-transplant&#xD;
&#xD;
                    -  Immune protein electrophoresis (IPEP) is required to show that M-component&#xD;
                       is the same on day 60 post-transplant as pre-transplant&#xD;
&#xD;
                    -  Residual (&gt; 5%) plasma cells in bone marrow&#xD;
&#xD;
               -  Relapsed non-Hodgkin lymphoma or Hodgkin lymphoma&#xD;
&#xD;
                    -  Relapse or progression of disease must be evidenced within 3 months prior to&#xD;
                       donor lymphocyte infusion by physical exam, radiographic studies, or&#xD;
                       molecular studies&#xD;
&#xD;
                         -  Tumor should be re-biopsied to determine histology&#xD;
&#xD;
                    -  If Epstein-Barr virus (EBV) lymphoma is suspected, peripheral blood must be&#xD;
                       assayed for EBV genome (i.e., EBV DNA testing by PCR) within the past 30&#xD;
                       days&#xD;
&#xD;
               -  EBV infection with associated pancytopenia&#xD;
&#xD;
                    -  Persistent or refractory pancytopenia with EBV genome detected by PCR in the&#xD;
                       peripheral blood&#xD;
&#xD;
                         -  Refractory pancytopenia is defined as pancytopenia that is poorly&#xD;
                            responsive to growth factors and/or transfusions&#xD;
&#xD;
               -  EBV lymphoproliferative disorder&#xD;
&#xD;
                    -  Clonal lymphadenopathy that is refractory to standard therapy with acyclovir&#xD;
                       and immunoglobulin (DLI may be given with rituximab)&#xD;
&#xD;
          -  Not a candidate for repeat ASCT&#xD;
&#xD;
               -  Chimerism status is not required for determining eligibility for DLI&#xD;
&#xD;
          -  Patients eligible for allogeneic ASCT, but for whom DLI is offered as the first&#xD;
             option, should have full donor chimerism at relapse or after therapy for relapsed&#xD;
             disease&#xD;
&#xD;
          -  Patients with relapsed underlying disease after transplant who achieved remission&#xD;
             after chemotherapy are allowed&#xD;
&#xD;
          -  No CNS recurrence that is not cleared by standard chemotherapy&#xD;
&#xD;
               -  CNS remission status must be maintained for 2 weeks&#xD;
&#xD;
          -  Original hematopoietic progenitor stem cell donor must be available for cell donation&#xD;
&#xD;
               -  No syngeneic donors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy â‰¥ 8 weeks&#xD;
&#xD;
          -  Creatinine &lt; 3 mg/dL&#xD;
&#xD;
          -  ABO/Rh and CMV IgG/IgM status known&#xD;
&#xD;
          -  No HIV1 and HIV2 antibody&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months (males) or 6&#xD;
             months (females) after completion of study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>July 29, 2020</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2020</results_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT00534118/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Multiple DLI</title>
          <description>Accruals where the patient received 2-4 donor lymphocyte infusions Arm includes total number of infusions</description>
        </group>
        <group group_id="P2">
          <title>Single DLI</title>
          <description>accruals where the patient received only one donor lymphocyte infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants can be accrued more than once; Accruals are based on the number of times the participant had a treatment (DLI) cycle that was evaluable (ie. &gt;8 weeks between infusions per the protocol). DLIs which were given &lt;8 weeks apart counted as one accrual.</population>
      <group_list>
        <group group_id="B1">
          <title>Multiple DLI</title>
          <description>Accruals where the patient received 2-4 donor lymphocyte infusions Arm includes total number of infusions</description>
        </group>
        <group group_id="B2">
          <title>Single DLI</title>
          <description>Accruals where the patient received only one donor lymphocyte infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="16" upper_limit="66"/>
                    <measurement group_id="B2" value="53.5" lower_limit="9" upper_limit="68"/>
                    <measurement group_id="B3" value="51" lower_limit="9" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Acute Myeloid Leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myelodysplastic Syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Hodgkin Leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acute Lymphoblastic Leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic Myeloid Leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hodgkin Lymphoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prolymphocytic Leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Remission Rate</title>
        <description>continued or induced complete remission after DLI</description>
        <time_frame>100 days post DLI</time_frame>
        <population>Each accrual is evaluable independently, some patients in both the Multiple and Single DLI are accrued more than once; total unique patients in multiple DLI is 15 and in single DLI is 12</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple DLI</title>
            <description>Accruals where the patient received 2-4 donor lymphocyte infusions Arm includes total number of infusions</description>
          </group>
          <group group_id="O2">
            <title>Single DLI</title>
            <description>accruals where the patient received only one donor lymphocyte infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission Rate</title>
          <description>continued or induced complete remission after DLI</description>
          <population>Each accrual is evaluable independently, some patients in both the Multiple and Single DLI are accrued more than once; total unique patients in multiple DLI is 15 and in single DLI is 12</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Complete Response in Months (Maximum 12)</title>
        <description>For participants who achieve a complete remission after DLI, the duration of time until 1) relapse or 2) death in remission or 3) subsequent DLI or 4) last followup (at 1 year after DLI)</description>
        <time_frame>1 year post DLI</time_frame>
        <population>Accruals which achieved a continued or induced complete remission at Day +100 after DLI, patients are censored at death in remission or at time of subsequent DLI</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple DLI - Complete Responders</title>
            <description>Duration of time patients who achieved a complete remission by day +100 after DLI maintained that remission</description>
          </group>
          <group group_id="O2">
            <title>Single DLI - Complete Responders</title>
            <description>Duration of time patients who achieved a complete remission by day +100 after DLI maintained that remission</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Complete Response in Months (Maximum 12)</title>
          <description>For participants who achieve a complete remission after DLI, the duration of time until 1) relapse or 2) death in remission or 3) subsequent DLI or 4) last followup (at 1 year after DLI)</description>
          <population>Accruals which achieved a continued or induced complete remission at Day +100 after DLI, patients are censored at death in remission or at time of subsequent DLI</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="1.7" upper_limit="12"/>
                    <measurement group_id="O2" value="9" lower_limit="1.0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-host Disease</title>
        <description>development of grade III-IV acute graft-versus-host disease (GVHD) per Glucksberg criteria</description>
        <time_frame>100 days post DLI</time_frame>
        <population>Each accrual is evaluable for acute GVHD grade III-IV</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple DLI</title>
            <description>Accruals where the patient received 2-4 donor lymphocyte infusions Arm includes total number of infusions</description>
          </group>
          <group group_id="O2">
            <title>Single DLI</title>
            <description>accruals where the patient received only one donor lymphocyte infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-host Disease</title>
          <description>development of grade III-IV acute graft-versus-host disease (GVHD) per Glucksberg criteria</description>
          <population>Each accrual is evaluable for acute GVHD grade III-IV</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All cause mortality includes individual participants who experienced death due to any cause before 3 years after first DLI and is the only SAE/AE captured per protocol</time_frame>
      <desc>All cause mortality includes individual participants who experienced death due to any cause before 3 years after first DLI</desc>
      <group_list>
        <group group_id="E1">
          <title>Multiple DLI</title>
          <description>Accruals where the patient received 2-4 donor lymphocyte infusions Arm includes total number of infusions</description>
        </group>
        <group group_id="E2">
          <title>Single DLI</title>
          <description>accruals where the patient received only one donor lymphocyte infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All cause mortality by 3 years after first DLI</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa Hahn</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
      <email>theresa.hahn@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

